Abstract Search

ba0001pp436 | Osteoporosis: treatment | ECTS2013

Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials

Recknor Christopher , Roux Christian , Ho Pei-Ran , Hall Jesse , Bone Henry , Bonnick Sydney , van den Bergh Joop , Ferreira Irene , Wagman Rachel , Brown Jacques P

: In osteoporosis, poor adherence to bisphosphonate (BP) therapy is common, and is associated with poor outcomes and increased treatment costs (Siris 2006; Recker 2005). Although compliance is improved with monthly vs weekly dosing (Reginster 2008), no evidence suggests cycling through BP agents offers therapeutic benefit, assessed by bone mineral density (BMD). In two randomized, open-label studies in postmenopausal women aged ≥55 years previously treated with, but subo...

0 shares

ba0001pp451 | Osteoporosis: treatment | ECTS2013

Estimation of vertebral and femoral strength during the first three years of denosumab therapy using an alternative smooth non-linear finite element methodology

Zysset Philippe , Pahr Dieter , Engelke Klaus , Genant Harry , McClung Michael , Kendler David , Recknor Christopher , Kinzl Michael , Schwiedrzik Jakob , Museyko Oleg , Wang Andrea , Libanati Cesar

Denosumab subcutaneous administration every 6 months reduced the incidence of new fractures in postmenopausal women with osteoporosis by 68% at the spine and 40% at the hip over 36 months compared with placebo in the FREEDOM study (Cummings et al., NEJM, 2009:361:756). This efficacy was supported by differential improvements from baseline in vertebral and femoral strength at 36 months (18.2 and 8.6%, respectively) estimated by an established voxel-based finit...

0 shares

ba0003OP7 | Clinical | ECTS2014

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Brown Jacques P , Bolognese Michael A , Ho Pei-Ran , Roux Christian , Bone Henry G , Bonnick Sydney L , van den Bergh Joop , Ferreira Irene , Ghelani Prayashi , Dakin Paula , Wagman Rachel B , Recknor Christopher

see PP357....

0 shares

ba0003pp357 | Osteoporosis: treatment | ECTS2014

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Brown Jacques P , Bolognese Michael A , Ho Pei-Ran , Roux Christian , Bone Henry G , Bonnick Sydney L , van den Bergh Joop , Ferreira Irene , Ghelani Prayashi , Dakin Paula , Wagman Rachel B , Recknor Christopher

Low bone mineral density (BMD) is an important and modifiable risk factor for fracture in postmenopausal women with osteoporosis. Denosumab (DMAb) shows a stronger relationship between BMD increases and antifracture efficacy than oral bisphosphonate (BP) therapies. Subjects who remain at higher risk of fracture despite current BP therapy need treatment. In two studies, DMAb significantly increased BMD and decreased bone turnover markers vs a BP (ibandronate (IBN) or risedronat...

0 shares

Bone Abstracts

Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials

Estimation of vertebral and femoral strength during the first three years of denosumab therapy using an alternative smooth non-linear finite element methodology

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

BiosciAbstracts